The efficacy and safety of bupropion sustained-release formulation for the treatment of major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study in Asian patients

Yoshifumi Koshino¹
Won-Myong Bahk²
Hideaki Sakai³
Takayuki Kobayashi⁴

¹Iris Medical Clinic, Kanazawa University, Ishikawa, Japan; ²Yeouido St Mary's Hospital, The Catholic University of Korea, Seoul, South Korea; ³Meguro Station East Mental Clinic, Shinagawa, Tokyo, Japan; ⁴Medicines Development (Neurosciences), Development and Medical Affairs, GlaxoSmithKline, Shibuya, Tokyo, Japan

Abstract: This study was conducted to compare the efficacy and safety of bupropion sustained-release (SR) formulation orally administered at daily doses of 150 mg/day (once daily) and 300 mg/day (150 mg twice daily) for 8 weeks versus placebo in Asian patients with major depressive disorder. The mean change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score at week 8 was compared between each of the bupropion SR dose groups and the placebo group using an analysis of covariance with the multiplicity adjustment by Dunnett’s step-down procedure. A total of 569 subjects met all of the inclusion criteria and proceeded to the treatment phase. The subjects proceeding to the treatment phase included 454 Japanese patients and 115 Korean patients. There was no statistically significant difference between each of the bupropion SR dose groups and the placebo group in the primary efficacy endpoint of change from baseline in MADRS total score at week 8. Similar results were generally obtained for all of the secondary efficacy endpoints. The secondary analysis and the other subgroup analysis did not show a statistically significant difference in efficacy. There was no substantial difference in the type, severity, and incidence of adverse events (AEs) between the bupropion SR dose groups and the placebo group, which indicates a favorable safety profile for bupropion SR. There were no significant findings in subjects treated with bupropion SR in regard to sexual dysfunction, weight change, and withdrawal syndrome, which are frequently recognized as clinical concerns associated with selective serotonin reuptake inhibitors, widely used for the treatment of depression.

Keywords: bupropion SR, placebo, major depressive disorder, Japan, Korea

Introduction
Bupropion hydrochloride (GlaxoSmithKline plc, Brentford, Middlesex, UK) is an anti-depressant of the aminoketone class, chemically unrelated to tricyclic antidepressants (TCAs), tetracyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), serotonin noradrenaline reuptake inhibitors (SNRIs), or other known antidepressant agents. Bupropion is an inhibitor of dopamine and noradrenaline reuptake. Although bupropion is recognized as an important treatment option for the treatment of major depressive disorder (MDD), it is not yet available in Japan. However, bupropion is already available in South Korea, but no randomized placebo-controlled trial has been conducted in Korean patients with MDD.
Bupropion was first approved in the USA in 1985 as Wellbutrin, a three times daily dosing formulation. Subsequently, Wellbutrin sustained release (SR), which is the investigational product of this study, was developed as a twice-daily SR formulation that can achieve an area under the concentration–time curve (AUC) comparable to that of Wellbutrin, with a lower maximum plasma concentration.

The primary objective of this study was to investigate the efficacy of oral bupropion SR at doses of 150 mg/day (given as a single daily dose) and 300 mg/day (given as 150 mg twice daily) for 8 weeks compared with placebo, using the Montgomery–Åsberg Depression Rating Scale (MADRS) as an indicator, in a multicenter, randomized, double-blind, parallel-group study in Japanese and Korean patients with MDD. The dosage and administration used for this study were consistent with the approved dosage and administration for the treatment of MDD in the USA. This study was carried out as the first Asian collaboration study of bupropion patients with MDD in Japan and South Korea.

Materials and methods

After obtaining consent from the subject and his/her proxy consent (if the subject was aged <20 years at the time of giving consent), the investigator registered the anonymized subject number via a centralized registration and randomization system. Following confirmation of eligibility to participate in the study by investigators, subjects were randomly allocated into three groups: bupropion SR 150 mg/day (BUP150), 300 mg/day (BUP300), or placebo, in a 1:1:1 ratio at the start of the treatment phase (week 0) (ClinicalTrials.gov identifier: NCT01138007). Investigational products were administered twice daily, in the morning and in the evening, with an interval of at least 8 hours between successive doses during the treatment phase.

Subjects were eligible for enrollment in the study if the following criteria were met at the start of the wash-out phase: a diagnosis of MDD based on the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR); a total score of ≥20 on the Interactive Voice Response (IVR)-based Hamilton Rating Scale for Depression (HAM-D; 17 items); a total score of ≥25 on the Inventory of Depressive Symptomatology–Self Report (IDS-SR); a score of ≥1 on at least four of five items on the five-item subscale of the IDS-SR (items 19, 20, 21, 22, and 30), and a total score of ≥7 on the five-item subscale of the IDS-SR; a Clinical Global Impression Severity of Illness (CGI-SI) score of ≥4 (“Moderately ill” or much worse); a current major depressive episode duration of ≥8 weeks and <24 months; and aged ≥18 and <65 years.

Subjects meeting any of the following criteria could not be enrolled in the study: past history of seizure or seizure disorder; more than a single febrile seizure in infancy; cerebral tumor; head/brain injury (traumatic); a history or current diagnosis of anorexia nervosa or bulimia; a primary DSM-IV diagnosis of, or received treatment for, panic disorder; obsessive compulsive disorder; post-traumatic stress disorder or acute stress disorder 12 months before the start of the run-in phase; a DSM-IV diagnosis of schizophrenia, or other psychotic disorder(s), including bipolar disorder; a history of, or currently has, manic episode(s); poses a current serious suicidal risk or has made a suicide attempt within the past 6 months; pregnant, possibly pregnant, lactating women, or females who want to become pregnant during the study. Concomitant use of drugs considered to have influence on efficacy evaluation was prohibited during the study periods.

Subjects were admitted to proceed to the treatment phase if the following criteria were met at the start of the treatment phase (visit 2, week 0): a total score of ≥20 of the IVR-based HAM-D (17 items); IVR-based HAM-D (17 items) total score did not increase or decrease by ≥25% between visit 1 and visit 2; a total score of ≥25 on the IDS-SR; a score of ≥1 on at least four of five items on the five-item subscale of the IDS-SR and a total score of ≥7 on the five-item subscale of the IDS-SR; and a CGI-SI score of ≥4 (“Moderately ill” or much worse).

In order to avoid rater bias in the primary rating scale of the MADRS among investigators, we provided hands-on training courses to all study investigators prior to involvement in this study.

Investigators were required to use the MINI (Mini International Neuropsychiatric Interview) for the diagnosis of MDD, and this was explicitly defined in the study protocol.

The study protocol was prepared according to the International Conference on Harmonisation – Good Clinical Practice guidelines and reviewed and approved by the institutional review boards of the participating institutions prior to study initiation. The investigator ensured potential subjects of the study were fully informed, including the provision of written information; written informed consent was obtained from all patients prior to participation in the study. This study...
was conducted in accordance with the guiding principles of the Declaration of Helsinki (2008).

Statistical methods
Sample size considerations
The mean differences to be detected between each of the bupropion SR dose groups and the placebo group was set at 2.7, and a standard deviation of 9.0 for each group was assumed for the changes from baseline in MADRS total score at week 8. A total of 564 subjects (188 subjects per group) were required to test the statistical hypothesis of this study, with 80% power in comparison of each of the bupropion SR dose group versus placebo group, with multiplicity adjustment using Dunnett’s step-down closed testing procedure.

Efficacy measures
Primary endpoint
The primary endpoint of this study was the change from baseline in MADRS total score at week 8. The primary comparisons between the BUP150 and placebo groups, and between the BUP300 and placebo groups were made using the intent-to-treat (ITT) data set with missing values imputed using the last observation carried forward (LOCF) method. The mean change from baseline in MADRS total score at week 8 was compared between each of the bupropion SR dose groups and the placebo group using an analysis of covariance (ANCOVA) with Dunnett’s step-down procedure to control inflation in the family-wise type I error rate. The procedure started with the comparison of primary interest and then stepping-down to ‘the least significant’ comparison only when the previous comparison was statistically significant. The ANCOVA model included region (country) and baseline value of MADRS total score (week 0) as covariates.

Secondary endpoints
For rating scales, observed scores and their change from baseline scores were summarized by treatment at each scheduled assessment point. The mean differences between each of the bupropion SR dose groups and the placebo group were estimated, along with 95% confidence intervals, and the statistical comparison was made using ANCOVA. The ANCOVA models included region and baseline value as covariates.

Safety measures
Serious adverse events (SAEs) were recorded from the date the informed consent was obtained to the last follow-up contact, and other adverse events (AEs) were documented from the start of the investigational product to the end of the follow-up period. AEs, including SAEs, were recorded with non-leading questions. AEs leading to discontinuation of investigational product or withdrawal from the study were also documented.

Clinical laboratory data, vital sign data, and 12-lead electrocardiograph (ECG) findings were summarized at each scheduled assessment point.

Results
Demography
A total of 569 subjects were randomized to one of the three treatment groups: 187 in the placebo group, 190 in the BUP150 group, and 192 in the BUP300 group. Four subjects (one in the placebo group, three in the BUP300 group) who had not taken any investigational product were excluded from the safety-analysis population (SP). Among the SP, one subject in the BUP300 group for whom no efficacy observations had been recorded was excluded from the ITT analysis.

In the ITT analysis, there was no imbalance observed between treatment groups for any demographic and baseline factors (Table 1).

On subgroup analysis between the countries, the mean ages of the subjects were slightly higher in Korean subjects: 38.7, 42.6, and 42.3 years in the placebo, BUP150, and BUP300 groups, respectively, and 35.4, 36.1, and 36.8 years, respectively, in Japanese subjects. The proportion of female subjects was higher in Korean subjects: 70%, 72%, and 75% in the placebo, BUP150, and BUP300 groups, respectively, and 50%, 47%, and 51%, respectively, in Japanese subjects. Except for the mean age and the ratio of males to females, subject demographic and baseline factors showed similar profiles in both countries.

Efficacy results
The adjusted mean (standard error [SE]) of the change from baseline and comparison between each treatment group of bupropion SR over placebo are shown in Table 2. The mean MADRS total score decreased from baseline in all groups; however, there was no statistically significant difference between the placebo group and each treatment group. Since the first comparison (placebo versus BUP150) failed to show significance, the second comparison (placebo vs BUP300) was not performed, in order to control type I error rate.

Results of the secondary efficacy variables were consistent with results of the primary analysis.
### Table 1: Summary of pretreatment demographic and baseline characteristics (intent-to-treat population)

<table>
<thead>
<tr>
<th></th>
<th>Placebo (n = 186)</th>
<th>BUP150 (n = 190)</th>
<th>BUP300 (n = 188)</th>
<th>Total (n = 564)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Country</strong> (n)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Japan</td>
<td>149</td>
<td>154</td>
<td>148</td>
<td>451</td>
</tr>
<tr>
<td>South Korea</td>
<td>37</td>
<td>36</td>
<td>40</td>
<td>113</td>
</tr>
<tr>
<td><strong>Age (years)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>37.9</td>
<td>36.0</td>
<td>37.5</td>
<td>37.1</td>
</tr>
<tr>
<td>SD</td>
<td>11.09</td>
<td>10.42</td>
<td>10.96</td>
<td>10.84</td>
</tr>
<tr>
<td>Median</td>
<td>37.0</td>
<td>35.0</td>
<td>36.0</td>
<td>36.0</td>
</tr>
<tr>
<td>Min</td>
<td>20</td>
<td>18</td>
<td>21</td>
<td>18</td>
</tr>
<tr>
<td>Max</td>
<td>63</td>
<td>64</td>
<td>64</td>
<td>64</td>
</tr>
<tr>
<td><strong>Sex</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>101 (54%)</td>
<td>98 (52%)</td>
<td>105 (56%)</td>
<td>304 (54%)</td>
</tr>
<tr>
<td>Male</td>
<td>85 (46%)</td>
<td>92 (48%)</td>
<td>93 (44%)</td>
<td>261 (46%)</td>
</tr>
<tr>
<td><strong>Weight (kg)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>60.19</td>
<td>61.01</td>
<td>62.00</td>
<td>61.07</td>
</tr>
<tr>
<td>SD</td>
<td>11.678</td>
<td>12.793</td>
<td>13.164</td>
<td>12.564</td>
</tr>
<tr>
<td>Median</td>
<td>58.45</td>
<td>59.00</td>
<td>59.95</td>
<td>59.00</td>
</tr>
<tr>
<td>Min</td>
<td>37.5</td>
<td>39.0</td>
<td>38.8</td>
<td>37.5</td>
</tr>
<tr>
<td>Max</td>
<td>95.2</td>
<td>107.4</td>
<td>102.0</td>
<td>107.4</td>
</tr>
<tr>
<td><strong>DSM-IV-TR diagnosis</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>296.20</td>
<td>1 (&lt;1%)</td>
<td>0 (&lt;1%)</td>
<td>1 (&lt;1%)</td>
<td>2 (&lt;1%)</td>
</tr>
<tr>
<td>296.21</td>
<td>0 (1%)</td>
<td>0 (1%)</td>
<td>0 (1%)</td>
<td>0 (1%)</td>
</tr>
<tr>
<td>296.22</td>
<td>83 (45%)</td>
<td>84 (45%)</td>
<td>71 (38%)</td>
<td>238 (42%)</td>
</tr>
<tr>
<td>296.23</td>
<td>14 (8%)</td>
<td>15 (8%)</td>
<td>11 (6%)</td>
<td>40 (7%)</td>
</tr>
<tr>
<td>296.31</td>
<td>0 (1%)</td>
<td>2 (1%)</td>
<td>0 (1%)</td>
<td>2 (&lt;1%)</td>
</tr>
<tr>
<td>296.32</td>
<td>81 (44%)</td>
<td>76 (40%)</td>
<td>77 (41%)</td>
<td>234 (41%)</td>
</tr>
<tr>
<td>296.33</td>
<td>7 (4%)</td>
<td>12 (6%)</td>
<td>28 (15%)</td>
<td>47 (8%)</td>
</tr>
<tr>
<td><strong>Number of previous depressive episodes (not including current episode)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>98 (53%)</td>
<td>100 (53%)</td>
<td>83 (44%)</td>
<td>281 (50%)</td>
</tr>
<tr>
<td>1</td>
<td>64 (34%)</td>
<td>56 (29%)</td>
<td>71 (38%)</td>
<td>191 (34%)</td>
</tr>
<tr>
<td>2</td>
<td>12 (6%)</td>
<td>22 (12%)</td>
<td>23 (12%)</td>
<td>57 (10%)</td>
</tr>
<tr>
<td>3</td>
<td>8 (4%)</td>
<td>6 (3%)</td>
<td>7 (4%)</td>
<td>21 (4%)</td>
</tr>
<tr>
<td>4 or more</td>
<td>4 (2%)</td>
<td>6 (3%)</td>
<td>4 (2%)</td>
<td>14 (2%)</td>
</tr>
<tr>
<td><strong>Duration of current major depressive episode (weeks)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>26.8</td>
<td>26.5</td>
<td>28.7</td>
<td>27.3</td>
</tr>
<tr>
<td>SD</td>
<td>19.44</td>
<td>19.18</td>
<td>22.27</td>
<td>20.33</td>
</tr>
<tr>
<td>Median</td>
<td>21.0</td>
<td>19.5</td>
<td>22.0</td>
<td>21.0</td>
</tr>
<tr>
<td>Min</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Max</td>
<td>100</td>
<td>98</td>
<td>101</td>
<td>101</td>
</tr>
</tbody>
</table>

Notes: DSM-IV TR diagnosis code. 296.2: Major depressive disorder, single episode; 296.3: Major depressive disorder, recurrent.

Abbreviations: BUP150, bupropion SR 150 mg/day (once daily); BUP300, bupropion SR 300 mg/day (twice daily); CI, confidence interval; ITT–LOCF, intent-to-treat, last observation carried forward; MADRS, Montgomery–Åsberg Depression Rating Scale; N/A, not applicable; SE, standard error; SR, sustained release; n, number; vs, versus.

### Table 2: Change from baseline in MADRS total score at week 8 (ITT–LOCF)

<table>
<thead>
<tr>
<th>Treatment group</th>
<th>n</th>
<th>Adjusted mean</th>
<th>SE</th>
<th>Difference vs placebo</th>
<th>Order of test</th>
<th>Adjusted 95% CI</th>
<th>Adjusted P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Mean</td>
<td>SE</td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>186</td>
<td>-13.9</td>
<td>0.77</td>
<td>-0.5</td>
<td>1.0</td>
<td>1.0</td>
<td>2-1.7</td>
</tr>
<tr>
<td>BUP150</td>
<td>190</td>
<td>-14.4</td>
<td>0.77</td>
<td>-0.5</td>
<td>1.0</td>
<td>1.0</td>
<td>2-1.7</td>
</tr>
<tr>
<td>BUP300</td>
<td>188</td>
<td>-12.9</td>
<td>0.76</td>
<td>-0.5</td>
<td>1.0</td>
<td>1.0</td>
<td>2-1.7</td>
</tr>
</tbody>
</table>

Notes: CIs and the adjusted P-values were based on Dunnnett’s step-down procedure. The statistical model included treatment group, region (country), and baseline value as explanatory variables. Since the first comparison (placebo vs BUP150) failed to show significance, the second comparison (placebo vs BUP300) was not performed, in order to control type I error rate.

Abbreviations: BUP150, bupropion SR 150 mg/day (once daily); BUP300, bupropion SR 300 mg/day (twice daily); CI, confidence interval; ITT–LOCF, intent-to-treat, last observation carried forward; MADRS, Montgomery–Åsberg Depression Rating Scale; N/A, not applicable; SE, standard error; SR, sustained release; n, number; vs, versus.

MADRS total scores, from week 1 through week 8, decreased over time in the bupropion SR treatment groups, but none of the reductions were significantly different from placebo (Table 3). IDS-SR total scores decreased over time in the bupropion SR treatment groups, but none of the reductions were significantly different from placebo (Table 4).

These efficacy results were consistent between the two countries participating in this study: Japan and Korea (Table 5).

Energy-related MADRS items (item 1, apparent sadness; item 2, reported sadness; item 6, concentration difficulties; item 7, lassitude; and item 8, inability to feel) were extracted to provide for the stratification analysis. The mean change from baseline in each item score of the five MADRS items decreased over time in every group. However, at any assessment point, there was no statistically significant difference in any item score between the placebo and each of the bupropion SR dose groups ($P = 0.054$ to 0.922).

MADRS responders were defined as “subject with a $\geq 50\%$ reduction from baseline in the MADRS total score at week 8” and the MADRS remitters were defined as “subject with $\leq 11$ MADRS total score at week 8”. There was no statistically significant difference between the placebo group and each of the bupropion SR dose groups in relation to MADRS responders and remitters (Table 6).

Post hoc subgroup analysis suggested that the patients who were diagnosed as “severe MDD” according to the DSM-IV-TR at baseline tended to show higher responses in bupropion treatment groups over placebo when comparing change in MADRS total scores from baseline. In this post hoc protocol compatible population analysis, without missing values complemented, the mean difference versus placebo in MADRS total scores at week 8 were $-4.9$ (SE 3.45) and $-2.6$ (SE 3.33) in the BUP150 and BUP300 groups, respectively. However, there was no statistical significance observed because of the limited number of subjects involved in the subgroup analysis.
Safety results

The percentage of subjects who reported at least one AE during the treatment phase was slightly higher in the BUP300 group (65%) than in the placebo (53%) and BUP150 (56%) groups. The most frequent AEs, which were reported in at least 5% of the subjects in any of the treatment groups, were nasopharyngitis, dry mouth, headache, nausea, constipation, tremor, and insomnia (Table 7). In all treatment groups, the majority of AEs reported were considered mild or moderate in intensity. There were no seizures or change to manic state observed in any of the treatment groups. Non-fatal SAEs were reported by 1% of subjects in the placebo group, 1% of subjects in the BUP150 group, and less than 1% of subjects in the BUP300 group. All of those SAEs resolved. The number of subjects reporting AEs leading to discontinuation of investigational product or withdrawal from the study was low and similar across treatment groups: four (2%) subjects

Table 3 Comparison of change from baseline in MADRS total scores (ITT–LOCF)

<table>
<thead>
<tr>
<th>Visit</th>
<th>Treatment group</th>
<th>n</th>
<th>Adjusted mean</th>
<th>SE</th>
<th>Difference vs placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Mean</td>
</tr>
<tr>
<td>Week 1</td>
<td>Placebo</td>
<td>186</td>
<td>-3.4</td>
<td>0.38</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>BUP150</td>
<td>190</td>
<td>-2.9</td>
<td>0.38</td>
<td>0.6</td>
</tr>
<tr>
<td></td>
<td>BUP300</td>
<td>188</td>
<td>-2.7</td>
<td>0.38</td>
<td>0.7</td>
</tr>
<tr>
<td>Week 2</td>
<td>Placebo</td>
<td>186</td>
<td>-6.2</td>
<td>0.47</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>BUP150</td>
<td>190</td>
<td>-5.0</td>
<td>0.47</td>
<td>1.2</td>
</tr>
<tr>
<td></td>
<td>BUP300</td>
<td>188</td>
<td>-5.0</td>
<td>0.47</td>
<td>1.2</td>
</tr>
<tr>
<td>Week 4</td>
<td>Placebo</td>
<td>186</td>
<td>-9.2</td>
<td>0.61</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>BUP150</td>
<td>190</td>
<td>-8.3</td>
<td>0.60</td>
<td>0.9</td>
</tr>
<tr>
<td></td>
<td>BUP300</td>
<td>188</td>
<td>-8.2</td>
<td>0.60</td>
<td>1.0</td>
</tr>
<tr>
<td>Week 6</td>
<td>Placebo</td>
<td>186</td>
<td>-11.8</td>
<td>0.70</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>BUP150</td>
<td>190</td>
<td>-11.7</td>
<td>0.70</td>
<td>0.1</td>
</tr>
<tr>
<td></td>
<td>BUP300</td>
<td>188</td>
<td>-11.1</td>
<td>0.69</td>
<td>0.7</td>
</tr>
<tr>
<td>Week 8</td>
<td>Placebo</td>
<td>186</td>
<td>-13.9</td>
<td>0.77</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>BUP150</td>
<td>190</td>
<td>-14.4</td>
<td>0.77</td>
<td>-0.5</td>
</tr>
<tr>
<td></td>
<td>BUP300</td>
<td>188</td>
<td>-12.9</td>
<td>0.76</td>
<td>1.0</td>
</tr>
</tbody>
</table>

Abbreviations: BUP150, bupropion SR 150 mg/day (once daily); BUP300, bupropion SR 150 mg/day (twice daily); CI, confidence interval; ITT–LOCF, intent-to-treat, last observation carried forward; MADRS, Montgomery–Åsberg Depression Rating Scale; SE, standard error; SR, sustained release; n, number; vs, versus.

Table 4 Comparison of change from baseline in IDS-SR total scores (ITT–LOCF)

<table>
<thead>
<tr>
<th>Visit</th>
<th>Treatment group</th>
<th>n</th>
<th>Adjusted mean</th>
<th>SE</th>
<th>Difference vs placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Mean</td>
</tr>
<tr>
<td>Week 1</td>
<td>Placebo</td>
<td>186</td>
<td>-4.8</td>
<td>0.57</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>BUP150</td>
<td>190</td>
<td>-4.2</td>
<td>0.57</td>
<td>0.6</td>
</tr>
<tr>
<td></td>
<td>BUP300</td>
<td>188</td>
<td>-3.9</td>
<td>0.57</td>
<td>0.9</td>
</tr>
<tr>
<td>Week 2</td>
<td>Placebo</td>
<td>186</td>
<td>-6.9</td>
<td>0.68</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>BUP150</td>
<td>190</td>
<td>-6.7</td>
<td>0.68</td>
<td>0.2</td>
</tr>
<tr>
<td></td>
<td>BUP300</td>
<td>188</td>
<td>-5.8</td>
<td>0.68</td>
<td>1.1</td>
</tr>
<tr>
<td>Week 4</td>
<td>Placebo</td>
<td>186</td>
<td>-9.7</td>
<td>0.82</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>BUP150</td>
<td>190</td>
<td>-9.3</td>
<td>0.82</td>
<td>0.4</td>
</tr>
<tr>
<td></td>
<td>BUP300</td>
<td>188</td>
<td>-8.2</td>
<td>0.81</td>
<td>1.5</td>
</tr>
<tr>
<td>Week 6</td>
<td>Placebo</td>
<td>186</td>
<td>-11.5</td>
<td>0.88</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>BUP150</td>
<td>190</td>
<td>-12.3</td>
<td>0.88</td>
<td>-0.8</td>
</tr>
<tr>
<td></td>
<td>BUP300</td>
<td>188</td>
<td>-10.9</td>
<td>0.87</td>
<td>0.5</td>
</tr>
<tr>
<td>Week 8</td>
<td>Placebo</td>
<td>186</td>
<td>-13.6</td>
<td>0.95</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>BUP150</td>
<td>190</td>
<td>-14.5</td>
<td>0.95</td>
<td>-0.9</td>
</tr>
<tr>
<td></td>
<td>BUP300</td>
<td>188</td>
<td>-12.6</td>
<td>0.94</td>
<td>1.0</td>
</tr>
</tbody>
</table>

Notes: Adjusted means, differences, SEs, CIs, and P-values were based on analyses of covariance. For overall comparisons, statistical models included treatment, baseline value, and region as explanatory variables. For comparisons by region in Japan and Korea, statistical models included treatment and baseline value as explanatory variables.

Abbreviations: BUP150, bupropion SR 150 mg/day (once daily); BUP300, bupropion SR 150 mg/day (twice daily); CI, confidence interval; IDS-SR, Inventory of Depressive Symptomatology–Self Report; ITT–LOCF, intent-to-treat, last observation carried forward; SE, standard error; SR, sustained release; n, number; vs, versus.
in the placebo group, 12 (6%) in the BUP150 group, and nine (5%) in the BUP300 group.

Throughout the study period, there was no clinically meaningful change in any laboratory parameters or in any vital sign values.

### Discussion

A total of 569 subjects were enrolled in this Asian multinational study of bupropion SR for the treatment of MDD. The group proceeding to the treatment phase included 454 Japanese subjects and 115 Korean subjects. Although the mean ages of the Korean subject groups were slightly higher than those of the Japanese subject groups, and the proportion of women enrolled in the Korean subject groups was higher than that of the Japanese subject groups, no imbalance was noted in any demographic and baseline factors and there was no concern regarding the comparability of the treatment groups.

Use of the IVR HAM-D assessment at the screening phase succeeded in reducing the enrollment of subjects with mild depression, which is often reported as an important factor in causing high placebo response rates in clinical trials of antidepressants. The average MADRS total scores at baseline (week 0) were 31.9, 31.8, and 32.1 in the placebo, BUP150, and BUP300 groups, respectively. MADRS was employed for the primary assessment of depression in the treatment phase rather than the continuous use of the HAM-D, carrying over from the screening phase, in order to suppress potential rater’s bias.

There was no statistically significant difference between the placebo and each of the bupropion SR dose groups in the primary efficacy endpoint (change from baseline in MADRS total score at week 8). It has been reported that bupropion appears to be potentially beneficial in the treatment of MDD-related fatigue. However, no difference was shown between the placebo and each of the bupropion SR dose groups at any treatment visit in the mean change from baseline for MADRS item 7 (lassitude), which can be assumed to be a fatigue-related rating score. Nor did the secondary analysis and the other subgroup analysis provide a statistical significance in efficacy.

The most probable reason for our inability to show superiority of bupropion would be the so-called ‘placebo effect’. Taking into account the fact that the placebo effect has been increasing over time in clinical studies of bupropion, a high placebo effect may have affected the assessment of the efficacy of bupropion SR, although analyses for various factors performed did not provide any conclusive evidence. The authors were not able to detect a relationship between individual study settings and degree of placebo response. Further examination would be necessary to identify the potential factors inflating the placebo effect.

AEs were reported in 106 (56%) and 123 (65%) subjects in the BUP150 and BUP300 groups, respectively, and 103 (55%) subjects in the placebo group, which indicated that there was no substantial difference in the incidence of AEs between treatment groups. The AEs commonly reported in any treatment groups included nasopharyngitis, dry mouth, headache, nausea, constipation, and insomnia, which were similar to those reported in a meta-analysis of

### Table 5 Change from baseline in MADRS total score at week 8 stratified by region (ITT–LOCF)

<table>
<thead>
<tr>
<th>Treatment group</th>
<th>Japan</th>
<th>South Korea</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>Mean (SD)</td>
<td>Min, Max</td>
</tr>
<tr>
<td>Placebo</td>
<td>149</td>
<td>-14.9 (10.38)</td>
</tr>
<tr>
<td>BUP150</td>
<td>154</td>
<td>-15.2 (10.14)</td>
</tr>
<tr>
<td>BUP300</td>
<td>148</td>
<td>-13.9 (10.64)</td>
</tr>
</tbody>
</table>

**Abbreviations:** BUP150, bupropion SR 150 mg/day (once daily); BUP300, bupropion SR 150 mg/day (twice daily); CI, confidence interval; ITT–LOCF, intent-to-treat, last observation carried forward; MADRS, Montgomery–Åsberg Depression Rating Scale; SD, standard deviation; SR, sustained release; n, number; Min, minimum; Max, maximum.

### Table 6 Summary of treatment difference for MADRS responders and remitters at week 8 (ITT–LOCF)

<table>
<thead>
<tr>
<th>Treatment group</th>
<th>n</th>
<th>MADRS responder</th>
<th>Difference (%)</th>
<th>95% CI for difference (%)</th>
<th>MADRS remitter</th>
<th>Difference (%)</th>
<th>95% CI for difference (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>186</td>
<td>86 (46.2)</td>
<td>-</td>
<td>-</td>
<td>53 (28.5)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>BUP150</td>
<td>190</td>
<td>98 (51.6)</td>
<td>-5.3</td>
<td>-15.4, 4.7</td>
<td>60 (31.6)</td>
<td>-3.1</td>
<td>-12.3, 6.2</td>
</tr>
<tr>
<td>BUP300</td>
<td>188</td>
<td>82 (43.6)</td>
<td>2.6</td>
<td>-7.5, 12.7</td>
<td>56 (29.8)</td>
<td>-1.3</td>
<td>-10.5, 7.9</td>
</tr>
</tbody>
</table>

**Notes:** An MADRS responder is defined as a subject with a $\geq 50\%$ reduction from baseline in the MADRS total score at week 8. MADRS remitter is defined as a subject with $\leq 11$ MADRS total score at week 8.

**Abbreviations:** BUP150, bupropion SR 150 mg/day (once daily); BUP300, bupropion SR 150 mg/day (twice daily); CI, confidence interval; ITT–LOCF, intent-to-treat, last observation carried forward; MADRS, Montgomery–Åsberg Depression Rating Scale; SR, sustained release; vs, versus; n, number.
There were no seizures in any of the treatment groups. SAEs were reported in two subjects in the placebo group, two subjects in the BUP150 group, and one subject in the BUP300 group. All of these SAEs resolved. The incidence of suicidal ideation based on the Columbia Suicide Severity Rating Scale was similar between treatment groups, and there were no reports of completed suicide. There were no clinically significant findings in clinical laboratory parameters and vital signs.

These results concerning AEs, and the other safety findings in terms of their type, severity, and incidence, indicate a favorable safety profile for bupropion SR.

**Conclusion**

This study was carried out as the first Asian collaboration study of bupropion SR for the treatment of the patients with MDD. The mean change from baseline in MADRS total score at week 8 (ITT–LOCF), the primary efficacy endpoint, decreased in all of the three treatment groups (placebo, BUP150, and BUP300); however, there was no statistically significant difference between the placebo group and each of the bupropion SR dose groups. Similar results were generally obtained for all of the secondary efficacy endpoints.

There was no substantial difference in the type, severity, and incidence of AEs between the bupropion SR dose groups and the placebo group, which indicated a favorable safety profile for bupropion SR.

Although this study did not demonstrate superiority of bupropion SR over placebo, due to a high placebo response, the drug was well tolerated and no new safety concerns were identified in this Asian population.

**Acknowledgments and disclosure**

This study was funded and conducted by GlaxoSmithKline. All listed authors meet the criteria for authorship set forth by the International Committee for Medical Journal Editors. Yoshifumi Koshino received research funding from GlaxoSmithKline as a medical expert and sponsor's responsible medical officer. Won-Myong Bahk and Hideaki Sakai received grant support from GlaxoSmithKline as investigators. Takayuki Kobayashi is a full-time employee of GlaxoSmithKline. The authors deeply appreciate all the investigators participating in the study. The authors report no other conflicts of interest in this work.

**References**


---

**Table 7** Adverse events reported in at least 5% of the subjects in any treatment group (safety-analysis population)

<table>
<thead>
<tr>
<th>System organ class</th>
<th>Placebo (n = 186)</th>
<th>BUP150 (n = 190)</th>
<th>BUP300 (n = 189)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preferred term</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n (%) of subjects with any AE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>103 (55)</td>
<td>106 (56)</td>
<td>123 (65)</td>
</tr>
<tr>
<td>Nausea</td>
<td>39 (21)</td>
<td>47 (25)</td>
<td>63 (33)</td>
</tr>
<tr>
<td>Constipation</td>
<td>8 (4)</td>
<td>12 (6)</td>
<td>28 (15)</td>
</tr>
<tr>
<td>Headaches</td>
<td>8 (4)</td>
<td>12 (6)</td>
<td>28 (15)</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>35 (19)</td>
<td>26 (14)</td>
<td>29 (15)</td>
</tr>
<tr>
<td>Headache</td>
<td>13 (7)</td>
<td>16 (8)</td>
<td>19 (10)</td>
</tr>
<tr>
<td>Insomnia</td>
<td>6 (3)</td>
<td>0</td>
<td>10 (5)</td>
</tr>
</tbody>
</table>

**Abbreviations:** AE, adverse event; BUP150, bupropion SR 150 mg/day (once daily); BUP300, bupropion SR 150 mg/day (twice daily); n, number.